Semanteon Capital Management LP Acquires Shares of 36,439 Envista Holdings Co. (NYSE:NVST)

Semanteon Capital Management LP acquired a new stake in shares of Envista Holdings Co. (NYSE:NVST) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 36,439 shares of the company’s stock, valued at approximately $877,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NVST. Foundry Partners LLC bought a new position in shares of Envista during the fourth quarter valued at approximately $3,571,000. Raymond James & Associates grew its stake in shares of Envista by 820.6% during the fourth quarter. Raymond James & Associates now owns 408,218 shares of the company’s stock valued at $9,822,000 after buying an additional 363,875 shares during the last quarter. River Road Asset Management LLC bought a new position in shares of Envista during the fourth quarter valued at approximately $54,931,000. DAVENPORT & Co LLC bought a new position in shares of Envista during the fourth quarter valued at approximately $13,233,000. Finally, Blueshift Asset Management LLC grew its stake in shares of Envista by 168.7% during the third quarter. Blueshift Asset Management LLC now owns 41,524 shares of the company’s stock valued at $1,158,000 after buying an additional 26,073 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on NVST shares. UBS Group started coverage on Envista in a research note on Friday, January 5th. They issued a “neutral” rating and a $26.00 price objective on the stock. SVB Leerink started coverage on Envista in a research note on Monday, February 26th. They issued an “underperform” rating and a $19.00 price objective on the stock. Morgan Stanley cut Envista from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $33.00 to $21.00 in a research note on Friday. William Blair cut Envista from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 8th. Finally, Jefferies Financial Group cut Envista from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $30.00 to $23.00 in a research note on Friday, February 9th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Envista has an average rating of “Hold” and an average price target of $27.90.

Envista Stock Up 1.8 %

Shares of NVST traded up $0.37 during midday trading on Friday, hitting $20.39. 1,816,938 shares of the company’s stock traded hands, compared to its average volume of 2,303,126. Envista Holdings Co. has a 1 year low of $18.95 and a 1 year high of $38.68. The firm’s fifty day moving average is $20.95 and its 200-day moving average is $22.72. The company has a current ratio of 2.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $3.50 billion, a price-to-earnings ratio of -33.43, a price-to-earnings-growth ratio of 3.79 and a beta of 1.35.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.04). The business had revenue of $645.60 million for the quarter, compared to analysts’ expectations of $638.37 million. Envista had a negative net margin of 3.90% and a positive return on equity of 6.31%. The business’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.52 EPS. As a group, sell-side analysts anticipate that Envista Holdings Co. will post 1.43 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.